Recent Updates
Recently added Catalysts
EQ Positive Sentiment

Equillium to Participate in the 2026 Jefferies Global Healthcare Conference

Thursday, May 28, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Equillium, Inc. announced its participation in the 2026 Jefferies Global Healthcare Conference, scheduled for June 3, 2026. The management team will engage in a fireside chat and is available for investor meetings. This highlights Equillium's commitment to connecting with stakeholders and promoting its innovative therapies for autoimmune and inflammatory disorders.
Price reaction · baseline $2.63 (2026-05-27 close) · hit after-hours · clean, no other EQ news in the window
day 0 close
+8%
day 1 · peak
+10.3%
day 3
+6.1%

Conference Participation Details

Jefferies Global Healthcare Conference
Date: November 18, 2025
Time: 11:30 a.m. GMT / 6:30 a.m. ET
Location: London
Format: Fireside Chat

How to Access

Investors and the general public can listen to both sessions live at:

https://investor.viatris.com

Archived versions will be available following the live events for a limited time.

Market Sentiment Analysis

POSITIVE FACTORS

  • Equillium is actively engaging with investors.
  • Participation in a significant healthcare conference.
  • Focus on developing novel therapies for serious conditions.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+58%
120-day peak, hindsight
Typical move
2.1%
average across 2 past catalysts
Cash runway
~42 mo
Minimal dilution risk
Lead asset
BNZ132-1-40
Phase 1 · Safety and Tolerability in Healthy Subjects

Full Press Release Details

LA JOLLA, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on Wednesday, June 3, 2026 at 4:55pm EDT.
Members of the Equillium management team will be available to meet with investors who are registered to attend the conference.
About EquilliumEquillium is a biotechnology innovator with a mission to develop highly impactful therapies to treat severe autoimmune and inflammatory disorders.
For more information, visitwww.equilliumbio.com.

Investor ContactPJ KelleherLifeSci Advisors, LLC+1-617-430-7579pkelleher@lifesciadvisors.com

Frequently Asked Questions

When is Equillium participating in the conference?

Equillium will participate on June 3, 2026, at 4:55pm EDT.

What is the focus of Equillium's therapies?

Equillium develops therapies for severe autoimmune and inflammatory disorders.

Who can meet with Equillium's management team?

Registered investors attending the conference can meet with the management team.

Where can I find more information about Equillium?

More information is available on Equillium's website at equilliumbio.com.

ShareAdd on Google
Tags: EQ Viatris Investor Conferences Healthcare Equillium Jefferies Conference biotechnology autoimmune disorders investor relations
Last updated: May 28, 2026

Conference Timeline

Nov 11, 2025
UBS Global Healthcare Conference
8:45 AM ET • Fireside Chat
Nov 18, 2025
Jefferies Global Healthcare
11:30 AM GMT • London

Biotech snapshot

Cash runway
$57M liquidity · $1M/mo burn
~42 mo
Minimal dilution risk
Lead asset
BNZ132-1-40Phase 1
Safety and Tolerability in Healthy Subjects →

Catalyst track record

+58%
best trade around EQ's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for EQ.

See every catalyst's timing & PoA →